Asuragen said this week that it has signed a deal to work with Biogen Idec to identify "a potential companion diagnostic test" that may be used to choose patients likely to respond to an undisclosed Biogen Idec drug currently in clinical development.
“The integrated drug-diagnostic co-development strategy being pursued by Biogen Idec and Asuragen has enormous potential to help physicians identify patients that will benefit from specific cancer treatments, and will be another step towards delivering on the promise of personalized medicine,” Asuragen CEO Matt Winkler said in a statement.
Additional terms of the deal were not disclosed.
It was not clear whether the potential diagnostic would be based on microRNA expression patterns. Last year, Asuragen began marketing an miRNA-based test for differentiating pancreatitis from pancreatic ductal adenocarcinoma (see RNAi News, 5/2/2008).